Mavenclad (cladribine) – MIMS – New liver monitoring requirement
01/11/2022
Medicines for human use
Safety update
This article was produced by the HPRA for publication in the November edition of Monthly Index of Medical Specialties (MIMS) and describes new liver monitoring requirements to minimise risk of serious liver injury with Mavenclad (cladribine).